AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00100815
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: twice daily on days 1-14. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
Trial: NCT01647282
Drug: locally-applied minocycline HCl (1 mg)
RxNorm normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00826020
Drug: Omegaven™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Omegaven™, 50 or 100 mL bottle; 1gram/kg/day and is infused over 12-24 hours.
Trial: NCT04237090
Drug: Lactose pill
RxNorm normalized name: lactose Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural product number : 00501190
Trial: NCT01953341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo containing no active drug
Trial: NCT01830660
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01011660
Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
Trial: NCT00938379
Drug: 20% deet insect repellent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: skin-applied repellent lotion
Trial: NCT00938379
Drug: placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical base formulation of lotion but without any deet active
Trial: NCT01216280
Drug: placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 10 mg placebo capsules administered orally with water, b.i.d.
Trial: NCT00965094
Drug: Enteric Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)
Trial: NCT00965094
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used according to Israeli standards. A minimum dose of 5mg \[prednisone, or equivalent, was used throughout the study period.
Trial: NCT03996460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fifteen (15) patients in group 1 will receive the sachet of matching placebo ( equivalent to a capsule of placebosugar pill) orally daily for 12 weeks (90 days) without food.
Trial: NCT02491450
Drug: Heterosofir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 400 mg sofosbuvir
Trial: NCT04258098
Drug: Oral antibiotics ( Streptomycin ,metronidazole )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.
Trial: NCT00477217
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00982592
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00982592
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02929121
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)
Trial: NCT02929121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily tablet for 6 weeks: matching tablets containing no active ingredients
Trial: NCT03446573
Drug: DTG + 3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG+3TC is supplied as white, oval, film-coated, fixed dose combination tablet. The tablets will be available in packed high density polyethylene (HDPE) bottles with induction seals and child-resistant closures.
Trial: NCT03446573
Drug: TAF based regimen (TBR)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue to receive their TBR.
Trial: NCT03646188
Drug: Placebo-containing MNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering a placebo.
Trial: NCT03646188
Drug: 25 µg doxorubicin-containing MNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 25 µg of doxorubicin hydrochloride.
Trial: NCT03646188
Drug: 50 µg doxorubicin-containing MNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 50 µg of doxorubicin hydrochloride.
Trial: NCT03646188
Drug: 100 µg doxorubicin-containing MNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 100 µg of doxorubicin hydrochloride.
Trial: NCT03646188
Drug: 200 µg doxorubicin-containing MNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 200 µg of doxorubicin hydrochloride.
Trial: NCT03123588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anagrelide-placebo administered orally BID
Trial: NCT03123588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib-placebo administered orally BID.
Trial: NCT00741949
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution infusion
Trial: NCT02993302
Drug: 1α-D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients were given PTU and 1α-D3
Trial: NCT02993302
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients were given PTU and placebos
Trial: NCT00756444
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
Trial: NCT01018056
Drug: D-serine
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage schedule will be flexible with a maximum dose for each subject being 30 mg/kg/day. In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of capsules labeled as study drug, but containing either 250 or 500 mg tablets of D-serine or placebo; capsule content to be determined by patient's weight. No changes in dosage will be made during the final week of treatment.
Trial: NCT01018056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be formulated in look-alike capsules. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing additional placebo capsules.
Trial: NCT04260607
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Procedure~1. Baseline evaluation of suicidal severity (BSSI) \& degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~2. The placebo arms will receive a single dose of 100 cc of NS infused over 40 minutes.~3. Post Placebo infusion re-evaluation of outcome measures at four and twenty-four hours~4. Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~5. Post Normal Saline re-evaluation of outcome measure at one-week post infusion.
Trial: NCT03847090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day
Trial: NCT00609973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bid for 6 months
Trial: NCT02181738
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT03128346
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen
Trial: NCT03128346
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV, fentanyl
Trial: NCT03412890
Drug: Estradiol/norethindrone acetate
RxNorm normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing co-formulated tablet of E2 (1 mg) and NETA (0.5 mg) administered orally once daily
Trial: NCT00104715
Drug: antiandrogen therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03306121
Drug: TPF+CCRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive paclitaxel liposome (135mg/m2 on day 1) , cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles of induction chemotherapy before radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)
Trial: NCT00968942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Dose B) applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
Trial: NCT01968668
Drug: BAY94-8862
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg BAY94-8862 tablet once daily in the morning
Trial: NCT01968668
Drug: BAY94-8862
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg BAY94-8862 tablet once daily in the morning
Trial: NCT01968668
Drug: BAY94-8862
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg BAY94-8862 tablet once daily in the morning
Trial: NCT01237405
Drug: 99mTc-EC20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi). A total of three imaging scans were acquired: an early phase (at \~1 minute) SPECT/CT of both knees; a late phase (at \~60 minutes) SPECT/CT image of both knees; and a late phase (at \~80 minutes) planar image of the whole body was performed (anterior-posterior, and postero-anterior).
Trial: NCT02726295
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00016302
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT and orally
Trial: NCT00016302
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00016302
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00016302
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or orally
Trial: NCT00016302
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01554852
Drug: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 \& 12-15 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
Trial: NCT01968668
Drug: BAY94-8862
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg BAY94-8862 tablet once daily in the morning
Trial: NCT01968668
Drug: BAY94-8862
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg BAY94-8862 tablet once daily in the morning
Trial: NCT01968668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily in the morning
Trial: NCT01968668
Drug: BAY 94-8862
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg BAY 94-8862 tablet once daily in the morning
Trial: NCT01968668
Drug: BAY 94-8862
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg BAY 94-8862 tablet once daily in the morning
Trial: NCT01554852
Drug: Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1,8,15 (i.e. weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules. Initially 100 mg daily PO for 3 weeks, increasing to 200 mg daily PO Days 1-4 and 12-15 - dexamethasone 40 mg daily PO The cycle is repeated every 21 days
Trial: NCT01554852
Drug: Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1 \& 2, 8 \& 9, 15 \& 16 - carfilzomib 20\*/36 mg/m2\*\* IV (\*carfilzomib 20 mg/m2 is only administered on days 1 and 2 of cycle 1; \*\*carfilzomib will be dose capped at a body surface area of 2.2 m2) Days 1-21 - lenalidomide 25 mg daily PO Days 1-4, 8, 9 \& 15, 16 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
Trial: NCT01554852
Drug: Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 \& 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
Trial: NCT01554852
Drug: Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1, 8, 15, 22 (weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules; initially 50 mg daily PO for 4 weeks, increasing every 4 weeks by 50 mg increments to 200 mg daily PO Days 1-4 \& 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
Trial: NCT01554852
Drug: Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1, 4, 8 \& 11 - bortezomib 1.3 mg/m2 SC or IV Days 1, 8, 15 - cyclophosphamide 500 mg PO Days 1-2, 4-5, 8-9 \& 11-12 - dexamethasone 20 mg daily PO This cycle is repeated every 21 days
Trial: NCT02536352
Drug: Prenatal vitamin-mineral containing 3 mg fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal vitamin-mineral containing 3 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
Trial: NCT00088101
Drug: STA-5312
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04556825
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the arthroscopic operation was completed, a local normal saline injection with same ml was performed
Trial: NCT00377806
Drug: Diclofenac gel
RxNorm normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00060255
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: iv
Trial: NCT00728182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion
Trial: NCT02232633
Drug: BBI503
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02808026
Drug: CS-3150
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-3150 2.5 to 5mg, orally, once daily after breakfast
Trial: NCT05264584
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
Trial: NCT01933425
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03849456
Drug: GWP42006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution containing cannabidivarin 50 milligrams per milliliter (mg/mL) in sesame oil with anhydrous ethanol, sucralose, strawberry flavoring, and β-carotene.
Trial: NCT02366130
Drug: Hormone Therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single hormonal agent administered daily while on study. Physician to decide what type of hormone therapy participant will receive.
Trial: NCT03495323
Drug: LY3300054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3300054 is a monoclonal antibody that targets programmed cell death ligand 1 (
Trial: NCT00425854
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high dose once daily
Trial: NCT01386177
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules identical to MDMA or doxazosin
Trial: NCT00114478
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01951027
Drug: GX-G3 12.5 μg/kg or Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single SC injection
Trial: NCT01951027
Drug: GX-G3 25 μg/kg or Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single SC injection
Trial: NCT01951027
Drug: GX-G3 50 μg/kg or Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single SC injection
Trial: NCT01951027
Drug: GX-G3 100 μg/kg or Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single SC injection
Trial: NCT03921541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
Trial: NCT04618965
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
Trial: NCT03150797
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin
Trial: NCT03150797
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03993431
Drug: Bio-active cement
RxNorm normalized name: citric acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A cement used for crown cementation, specially recommended for pediatric esthetic crowns
Trial: NCT03993431
Drug: Packable glass ionomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glass ionomer cement with improved mechanical properties usually used for restoration of simple small cavities and in Atraumatic Restorative Treatment
Trial: NCT02264041
Drug: Cilobradine, low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02264041
Drug: Cilobradine, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05862441
Drug: AV2-SA2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV2 is a combination of FDA GRAS-label approved organic compounds (natural essential oils: carvone, eugenol, geraniol, and nerolidol) that is postulated to be able to prevent viral entry and proliferation by deactivating the infectious virions before they enter the cell. Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis. Implementation of AV2-SA combination therapy would ensure permanent lesion clearance by on the one hand inactivation of HPV by AV2, and on the other hand elimination of the lesion by SA treatment.
Trial: NCT02194088
Drug: Diclofenac and Atropine combination drug
RxNorm normalized name: pralidoxime and atropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac will be associated with a small dose of atropine 1.2mg
Trial: NCT02194088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each capsule of active medication, a capsule of placebo will be provided, identical looking.
Trial: NCT02170012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily dosing for 14 days
Trial: NCT05406999
Drug: ADT
RxNorm normalized name: Radtue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.
Trial: NCT05406999
Drug: Prednisolone tablets
RxNorm normalized name: Prednisolone Tablets
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg once daily, orally.
Trial: NCT01436292
Drug: 5% human albumin solution (HAS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level:~≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; \< 10 gr/L: 150 g of 5% HAS.